ASCO Study Confirms Importance Of Histology In Treatment Of Non Small Cell Lung Cancer With ALIMTA (pemetrexed For Injection)
Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved Eli Lilly and Company’s ALIMTA® (pemetrexed for injection), will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., May 30 — June 3, 2008.
More: continued here
Filed under: Lung Cancer on May 22nd, 2008